东海证券晨会纪要-20250821

Group 1: Healthcare and Biopharmaceutical Industry - The healthcare and biopharmaceutical sector saw an overall increase of 3.08% from August 11 to August 15, outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has risen by 25.02%, ranking fourth among 31 industries [5][6]. - The National Healthcare Security Administration announced the preliminary review list for the 2025 National Basic Medical Insurance and commercial insurance drug directories, with 534 drugs passing the basic insurance review and 121 passing the commercial insurance review. Notably, 79 drugs passed both reviews, including various innovative therapies [6][7]. - Investment recommendations focus on innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services, as the sector is expected to benefit from ongoing policy support for innovative drugs [7][9]. Group 2: Electronics Industry - The global smart glasses market experienced a remarkable growth of 110% year-on-year in the first half of 2025, with expectations of maintaining a compound annual growth rate of over 60% from 2024 to 2029. Meta leads the market with a 73% share [10][11]. - Domestic semiconductor equipment has achieved significant breakthroughs, including the mass production of 28nm electron beam measurement equipment and the testing of the first commercial electron beam lithography machine, enhancing China's semiconductor industry autonomy [12][13]. - The electronics sector outperformed the market with a 7.02% increase, driven by strong demand recovery and price stabilization. Key areas of focus include AI server supply chains, AIOT, equipment materials, and automotive electronics [14][15].